SONAR
2019
Study of Diabetic Nephropathy with Atrasentan
In 2,648 patients with type 2 diabetes and CKD selected for response, atrasentan reduced the composite of creatinine doubling or ESKD compared with placebo.
Result
Efficacy: Doubling of serum creatinine or ESKDHR 0.65 (95% CI 0.49-0.88) · P = 0.0047
Below 1 favours atrasentan, above 1 favours placebo.
Also reported: More fluid retention and oedema with atrasentan.
- Subtopic
- Endothelin antagonists
- Design
- Double-blind RCT, enrichment (responder) design
- Relevance
- Supporting: context rather than must-know.
- Source
- Heerspink HJL, et al. Lancet. 2019;393(10184):1937-1947.doi 10.1016/S0140-6736(19)30772-X
Discussion & critique
Proof of concept for selective endothelin-A antagonism; the enrichment design limits generalisability.